EZH2 and hepatocellular carcinoma: Strikingly, we found that co-administration of FGFR4 and EZH2 inhibitors synergistically repressed YAP signaling to induce HCC cell apoptosis, rather than regulating the upstream MST1/2 and LAST1/2 signaling (Fig. 5B-I and S8C).